This has generated interest in the development of therapies targeting HIFs, especially HIF2α, which when overexpressed upregulates oncogenes including SLC2A1, CCND1, VEGFA, CXCR4, and CXCL12 that support cancer progression through increased glucose transport and glycolysis, cell cycle progression, angiogenesis, and cell migration [13,14,15,16]. The gene discussed is EPAS1; the disease is cancer.